Weighted Approach for Estimating Effects in Principal Strata With Missing Data for a Categorical Post-Baseline Variable in Randomized Controlled Trials

References

• DeGroot A. S., and Scott, D. W. (2007), “Immunogenicity of Protein Therapeutics,” Trends in Immunology, 28, 482–490. DOI: 10.1016/j.it.2007.07.011.
   PubMed Web of Science ®Google Scholar
• Austin, P. C. (2009), “The Relative Ability of Different Propensity Score Methods to Balance Measured Covariates Between Treated and Untreated Subjects in Observational Studies,” Medical Decision Making, 29, 661–677. DOI: 10.1177/0272989X09341755.
   PubMed Web of Science ®Google Scholar
• Austin, P. C., and Stuart, E. A. (2015), “Moving Towards Best Practice When Using Inverse Probability of Treatment Weighting (iptw) Using the Propensity Score to Estimate Causal Treatment Effects in Observational Studies,” Statistics in Medicine, 34, 3661–3679. DOI: 10.1002/sim.6607.
   PubMed Web of Science ®Google Scholar
• Baker, M., Reynolds, H.M., Lumicisi, B., and Bryson, C.J. (2007), “Immunogenicity of Protein Therapeutics: The Key Causes, Consequences and Challenges,” Self/NonSelf, 1. DOI: 10.4161/self.1.4.13904.
   Google Scholar
• Bornkamp, B., and Bermann, G. (2020), “Estimating the Treatment Effect in a Subgroup Defined by an Early Post-Baseline Biomarker Measurement in Randomized Clinical Trials With Time-to-Event Endpoint,” Statistics in Biopharmaceutical Research, 12, 19–28. DOI: 10.1080/19466315.2019.1575280.
   Web of Science ®Google Scholar
• Bornkamp, B., Rufibach, K., Lin, J., Mehrotra, D., Roychoudhury, S., Schmidli, H., Shentu, Y., and Wolbers, M. (2020), “Principal Stratum Strategy: Potential Role in Drug Development.” arXiv:2008.05406.
   Google Scholar
• Dillman, R. O. (2011), “Cancer Immunotherapy,” Cancer Biotherapy & Radiopharmaceuticals, 26, 1–24.
   PubMed Web of Science ®Google Scholar
• Ding, P., and Lu, J. (2017), “Principal Stratification Using Principal Scores,” Journal of the Royal Statistical Society, Series B, 79, 757–777. DOI: 10.1111/rssb.12191.
   Google Scholar
• Frangakis, C. E., and Rubin, D. B. (2002), “Principal Stratification in Causal Inference,” Biometrics, 58, 21–29. DOI: 10.1111/j.0006-341x.2002.00021.x.
   PubMed Web of Science ®Google Scholar
• ICH-Expert-Working-Group (2019), “Addendum on Estimands and Sensitivity Analysis in Clinical Trials to the Guideline on Statistical Principles for Clinical Trials.” ICH HARMONISED GUIDELINE 2019, available https://www.ich.org/page/efficacy-guidelines.
   Google Scholar
• Kalbfleisch, J., and Prentice, R. (2002), The Statistical Analysis of Failure Time Data (2nd ed.), NJ: Wiley.
   Google Scholar
• Larsen, K. G., and Josiassen, M. K. (2020), “A New Principal Stratum Estimand Investigating the Treatment Effect in Patients Who Would Comply, If Treated With a Specific Treatment,” Statistics in Biopharmaceutical Research, 12, 29–38. DOI: 10.1080/19466315.2019.1689847.
   Web of Science ®Google Scholar
• Lash, T., and Cole, S. (2009), “Immortal Person-Time in Studies of Cancer Outcomes,” Journal of Clinical Oncology, 27, 55–56. DOI: 10.1200/JCO.2009.24.1877.
   PubMed Web of Science ®Google Scholar
• Lin, D. Y., and Wei, L. J. (1989), “The Robust Inference for the Cox Proportional Hazards Model,” Journal of the American Statistical Association, 84, 1074–1078. DOI: 10.1080/01621459.1989.10478874.
   Web of Science ®Google Scholar
• Mattei, A., Mealli, F., and Ding, P. (2020), “Assessing Causal Effects in the Presence of Treatment Switching Through Principal Stratification.” arXiv:2002.11989.
   Google Scholar
• Rubin, D. B. (1974), “Estimating Causal Effects of Treatments in Randomized and Nonrandomized Studies,” Journal of Educational Psychology, 66, 688–701. DOI: 10.1037/h0037350.
   Web of Science ®Google Scholar
• Shankar, G., Arkin, S., Cocea, L., Devanarayan, V., Kirshner, S., Kromminga, A., Quarmby, V., Richards, S., Schneider, K., Subramanyam, M., Swanson, S., Verthelyi, D., and Yim, S. (2014), “Assessment and Reporting of the Clinical Immunogenicity of Therapeutic Proteins and Peptides Harmonized Terminology and Tactical Recommendations,” American Association of Pharmaceutical Scientists Journal, 14, 548–673.
   Google Scholar
• Socinski, M. A., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez-Abreu, D., Moro-Sibilot, D., Thomas, C. A., Barlesi, F., Finley, G., Kelsch, C., Lee, A., Coleman. S. Y., Deng, P., Shen, Y., Kowanetz, M., Lopez-Chavez, A., Sandler, A., Reck, M. (2018), “Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC,” New England Journal of Medicine, 378, 2288–2301. DOI: 10.1056/NEJMoa1716948.
   PubMed Web of Science ®Google Scholar
• Stuart, E. A., and Jo, B. (2015), “Assessing the Sensitivity of Methods for Estimating Principal Causal Effects,” Statistical Methods in Medical Research, 24, 657–674. DOI: 10.1177/0962280211421840.
   PubMed Web of Science ®Google Scholar